

The Antibacterial or Antifungal Effects of *Eurycoma longifolia* Root Extract

M Tzar, Y Hamidah, S Hartini, M Marianayati, A Nazrun

Citation

M Tzar, Y Hamidah, S Hartini, M Marianayati, A Nazrun. *The Antibacterial or Antifungal Effects of Eurycoma longifolia Root Extract*. The Internet Journal of Herbal and Plant Medicine. 2010 Volume 2 Number 1.

Abstract

Background:

Eurycoma longifolia Jack (*E. long*) has anticancer and antimalarial properties. Even though there are various claims of the ability of *E. long* to treat infections, there was only one study reported on its antibacterial effects, while there was no study on its antifungal effects. Therefore, we have conducted a study on the antibacterial and antifungal effects of using the current and most relevant clinical strains of bacteria and fungi. Methods: A macrobroth dilution method was used in this study. Three types of fungi (*Candida albicans*, *Candida glabrata* and *Candida krusei*) were tested against an aqueous extract of *E. long* root at concentrations of 10, 5, 2.5, 1.25 and 0.625 mg/mL. Six types of bacteria (methicillin-resistant *Staphylococcus aureus*, *Enterococcus faecium*, extended-spectrum beta lactamase-producing *Klebsiella pneumoniae*, group-1 beta lactamase-producing *Pseudomonas aeruginosa*, multidrug-resistant *Acinetobacter baumannii* and *Salmonella typhi*) were tested against an aqueous extract of *E. long* root at concentrations of 50, 25, 12.5, 6.25 and 3.125 mg/mL. The minimum inhibitory concentrations were determined by looking at the clarity of the final solutions. Results: There was no reduction in turbidity in all test tubes containing various concentrations of *E. long* root extract. Conclusion:

E. long root extract did not show any antibacterial or antifungal effect at concentrations of equal to or less than 50 mg/mL and 10 mg/mL, respectively.

INTRODUCTION

Eurycoma longifolia Jack or more commonly known among Malaysian locals as 'Tongkat Ali' is an herb frequently used in Malay traditional medicine. It is also known as 'paiak' or 'tung saw' in Thailand, 'pasak bumi' in Indonesia and 'cay ba bihn' in Vietnam¹. The herb that belongs to family Simaroubaceae may grow up to 10 metres high and about 10 centimetres in diameter. The pinnate leaves are spirally arranged while the brownish fruits are ovoid in shape². Several parts of *E. long* including the root, bark, leaves and fruits have been used traditionally to treat various diseases such as urinary tract infection, cancer, hypertension, indigestion, fever and itchiness. The most commonly used part of *E. long* is the root because it is said to have many active substances. Indeed, most *E. long* extracts that are available in the market are root extracts.

A study has shown that *E. long* was able to inhibit *Plasmodium falciparum* activity up to 80%³. *E. long* acted as an antimalarial agent by inhibiting ribosomal protein synthesis of *Plasmodium falciparum*⁴. However, *E. long* is

more popularly known as an aphrodisiac agent for men⁵.

From literature search, there were many studies done on the effects of *E. long* as aphrodisiac⁶, antimalarial⁷ and anticancer agents⁸. Nevertheless, studies on the effects of *E. long* as an antibacterial or antifungal agent are very scarce despite various claims being made of its effectiveness to treat many infections.

E. long extract was said to contain many potent, active substances to treat many diseases. Quassinoids active substances such as eurycomanone, 13, 21-dihydroeurycomanone and 13- α -epoxyeurycomanone⁹ have been shown to have antimalarial effects and were also thought to have antibacterial and antifungal activities. However, there was only one report by Farouk and Benafri¹⁰ who concluded that only the stem and leaf extracts of *E. long* have shown some antibacterial activities against several types of Gram-positive and Gram-negative bacteria. The root extract did not show any antibacterial effects. However, the bacterial strains used in the study did not have significant clinical importance. Therefore, it is more relevant and

meaningful to test *E. long* against bacterial strains that cause difficult-to-treat infections. In addition, there is also a need to study the antifungal effects of *E. long* as fungal infection is fast becoming an emerging infection especially among immunocompromised patients. To our knowledge, there was no published study on the antifungal effects of *E. long*. We prefer to use the aqueous root extract as this part was considered to contain many biochemical compounds with medicinal values and the standardized extract from the root is available¹¹. Most importantly, these studies should be performed according to strict microbiological standards to ensure reliability and reproducibility of the results.

MATERIALS AND METHODS

Powdered-form of aqueous *E. long* root extract (*Eurycoma longifolia* Jack) was obtained commercially (Phytes Biotek Sdn. Bhd., Shah Alam, Selangor, Malaysia). It was extracted from the root of the plant using a patented high pressure water extraction (US Patent No: US7,132,117 B2). The powder was dissolved in sterile distilled water to make a concentration of 100 mg/mL (w/v). The cloudy brown solution was then filtered with a membrane filter sized 0.45 µm (Supor® Membrane (Acrodisc®) Syringe Filter, Michigan, USA) to produce a clear and sterile solution. Double dilutions were performed to achieve solutions with various concentrations (100, 50, 25, 12.5 and 6.25 mg/mL, approximately 1 mL in each test tube).

FUNGAL INOCULUM PREPARATION AND INOCULATION

The method was adapted from M27-A3 document by the Clinical and Laboratory Standards Institute (CLSI)¹². The fungi used included *Candida albicans* (ATCC 10231), *Candida glabrata* (ATCC 64677) and a clinical isolate, *Candida krusei* (MB08022508). All three fungi were cultured onto Sabouraud Dextrose agar (SDA) (Oxoid, Hampshire, England) at 35°C in air for 24 hours. Several colonies were dissolved in 5 ml sterile distilled water. The suspension was vortexed and its turbidity adjusted visually to 0.5 McFarland (BioMerieux, France). This created a stock solution that contained approximately $1 - 5 \times 10^6$ yeast cells per ml. A working solution was created by diluting the stock solution by 1:100 and followed by 1:20 dilution using brain-heart infusion broth (BHIB) (Oxoid, Hampshire, England). The final solution contained approximately 5.0×10^2 to 2.5×10^3 yeast cells per ml.

For inoculation, 900 µL of the working solution was pipetted into six glass test tubes. 100 µl of *E. long* extract solutions

with five different concentrations (100, 50, 25, 12.5 and 6.25 mg/mL) were mixed with the first five glass test tubes. 100 µl of sterile distilled water was mixed with the sixth test tube, which acted as a positive control. Hence, the concentrations of *E. long* extract solutions had been diluted by 1:10 to 10, 5, 2.5, 1.25 and 0.625 mg/ml, respectively. Similarly, the inoculum density had been diluted by 10%. The test on each fungal isolate was done in triplicates. Negative control tubes were prepared by using uninoculated *E. long* solution 100 mg/mL (negative control 1) and uninoculated BHIB solution (negative control 2).

BACTERIAL INOCULUM PREPARATION AND INOCULATION

The method was adapted from M07-A8 document by the CLSI¹³. Six bacterial strains used were methicillin-resistant *Staphylococcus aureus* (MRSA) (UK 10002287), *Enterococcus faecium* (MB 10014383), extended-spectrum beta-lactamase (ESBL)-producing *Klebsiella pneumonia* (UK 10002259), group-1 beta-lactamase (G1BL)-producing *Pseudomonas aeruginosa* (MB 10015448), multidrug-resistant (MDR) *Acinetobacter baumannii* (MB 10011927) and *Salmonella typhi* (UKM 201031820). Several bacterial colonies were dissolved in Mueller-Hinton broth (MHB) (Oxoid, Hampshire, England). The turbidity was adjusted to 0.5 McFarland (BioMerieux, France). A 1:150 dilution was performed with another MHB solution to create a working solution that contained approximately 1×10^6 colony-forming units (CFU) per ml.

For inoculation step, 400 µl of the working solution were pipetted into six glass test tubes. 400 µl of *E. long* extract solution of different concentrations (100, 50, 25, 12.5 and 6.25 mg/ml) were mixed into the first five test tubes. 400 µl of sterile distilled water were mixed with the sixth test tube, which acted as a positive control. Hence, the concentrations of *E. long* extract solutions had been diluted by 1:2 to 50, 25, 12.5, 6.25 and 3.125 mg/ml, respectively. Similarly, the inoculum density had been diluted by 50%. The test on each bacterial isolate was done in triplicates. Negative control tubes were prepared by using uninoculated *E. long* solution 100 mg/ml (negative control 1) and uninoculated MHB solution (negative control 2).

INCUBATION AND RESULT INTERPRETATION

All test tubes were incubated in air at 35°C for 24 hours. After 24 hours, the turbidity in each test tube was compared visually with the positive control tube, against a background of three parallel, horizontal black lines. The degree of

turbidity was recorded as (-) clear, (+) turbid but the black lines were still visible or (++) too turbid to see the black lines. Minimum inhibitory concentration (MIC) was taken as the minimum *E. long* extract concentration required to inhibit any microbial growth (i.e. clear test tube).

RESULTS

All test tubes that contained mixtures of *E. long* extract and fungal isolates of *Candida albicans*, *Candida glabrata* and *Candida krusei* (tubes B, C, D, E and F) did not show any reduction in turbidity compared to the positive control (tube G). The negative controls (tubes A and H) remained clear. The MICs for all fungal strains tested were >10 mg/mL (Table 1).

All test tubes that contained mixtures of *E. long* extract and bacterial isolates of *Staphylococcus aureus*, *Enterococcus faecium*, *Klebsiella pneumonia*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Salmonella typhi* (tubes B, C, D, E and F) did not show any reduction in turbidity compared to the positive control (tube G). The negative controls (tubes A and H) remained clear. The MICs for all bacterial strains tested were >50 mg/mL (Table 2). An example of the findings for MDR-*Acinetobacter baumannii* is shown in Figure 1.

Figure 1

Figure 1. root extract test on MDR-. A = uninoculated 50 mg/mL (negative control 1); B-F = inoculated (50, 25, 12.5, 6.25, 3.25 mg/mL); G = bacterial suspension without (positive control); H = uninoculated Mueller-Hinton broth (negative control 2)



Figure 2

Table 1. Turbidity and minimum inhibitory concentration (MIC) for fungal isolates.

Isolate	<i>E. long</i> concentrations (mg/mL)						MIC (mg/mL)
	0	0.625	1.25	2.5	5	10	
<i>Candida albicans</i>	++	++	++	++	++	++	>10
<i>Candida glabrata</i>	++	++	++	++	++	++	>10
<i>Candida krusei</i>	++	++	++	++	++	++	>10

++ very turbid; + turbid; - clear

Figure 3

Table 2. Turbidity and minimum inhibitory concentration (MIC) for bacterial isolates.

Isolate	<i>E. long</i> concentrations (mg/mL)						MIC (mg/mL)
	0	3.125	6.25	12.5	25	50	
MRSA	++	++	++	++	++	++	>50
<i>Enterococcus faecium</i>	++	++	++	++	++	++	>50
ESBL <i>Klebsiella pneumonia</i>	++	++	++	++	++	++	>50
G1BL <i>Pseudomonas aeruginosa</i>	++	++	++	++	++	++	>50
MDR <i>Acinetobacter baumannii</i>	++	++	++	++	++	++	>50
<i>Salmonella typhi</i>	++	++	++	++	++	++	>50

++ very turbid; + turbid; - clear; MRSA, methicillin-resistant *Staphylococcus aureus*; ESBL,

extended-spectrum beta-lactamase; G1BL, group-1 beta-lactamase; MDR, multidrug-resistant.

DISCUSSION

The search for new antibiotics is badly needed to overcome problems posed by emerging resistant bacteria. For the past few decades, new antibiotic discoveries have become rare events. This has been attributed to strict approval and low returns on investment by pharmaceutical companies¹⁴. For the past 20 years, the number of new antibiotics in the market has plummeted to half^{15,16}. At the same time, the incidence of antibiotic resistance organisms is increasing, such as MRSA¹⁷ and *Pseudomonas aeruginosa*¹⁸. These two bacteria were included in our study.

Many methods and resources can be used to discover new antibiotics. It is very important for researchers to follow certain standardized guidelines in antimicrobial susceptibility testing to ensure the quality and reproducibility of an experiment. We had chosen to follow internationally accepted standards set by CLSI^{12,13}. Use of non-standardized methods will make it difficult to compare results among different experiments.

One of the reasons for the slow progress in new antibiotic discovery is the lack of study on natural products¹⁹. *E. long* is a traditional herb popular for its aphrodisiac effects but studies have shown that it also possesses anticancer, antimalarial and antibacterial activities. *E. long* extract contains an active substance, quassinoid, which is thought to be responsible for these effects. Based on a single report of antibacterial effect of *E. long* by Farouk and Benafri¹⁰, we

conducted a study on the antimicrobial effects of *E. long* on clinically important bacterial and fungal isolates. The six bacterial strains used in this study (viz. MRSA, *Enterococcus faecium*, ESBL-producing *Klebsiella pneumoniae*, GIBL-producing *Pseudomonas aeruginosa*, MDR-*Acinetobacter baumannii* and *Salmonella typhi*) often showed high levels of resistance to current antibiotic therapy whether in Malaysia or other countries. However, our study had shown that *E. long* root extract did not have any significant antibacterial effects to these six bacterial isolates. This finding is in agreement with the study by Farouk and Benafri who reported antibacterial effects were only observed from the leaf and stem, but not the root extracts of Tongkat Ali¹⁰.

Our study was the first on antifungal effects of *E. long* extract. Three different species of *Candida* were used viz. *Candida albicans*, *Candida glabrata* and *Candida krusei*. *Candida albicans* is the most common cause of fungal infections in humans. Studies have shown that *Candida albicans* was one of the three main species causing fungaemia^{20,21}. *Candida glabrata* and *Candida krusei* were selected because of their tendency to develop resistance to fluconazole, a commonly used antifungal drug. These three fungi often cause opportunistic infections in immunocompromised patients. *E. long* was hoped to be an alternative remedy for these patients. Unfortunately, *E. long* extract did not show any antifungal activities at the concentrations tested.

There were several limitations of our study. First, was the use of crude extract of *E. long*. This could have effectively reduced the concentrations of truly active antimicrobial compounds. Second, the choice of organisms tested. We had chosen to test *E. long* extracts against clinically resistant microorganisms. The *E. long* extract could potentially show some antimicrobial activities against clinically susceptible microorganisms. However, testing against 'normally' susceptible microorganisms would defeat the purpose of finding an alternative therapy for clinically-resistant strains.

CONCLUSIONS

E. long root extract did not show any antibacterial or antifungal activities at concentrations of 50 mg/mL or less and 10 mg/mL or less, respectively. Further studies can be done on extracts from different parts of *E. long* or with higher concentrations of extracts. However, the high concentration of *E. long* to be used in future studies must be reasonable to achieve if it is to be commercially produced as

a health supplement.

ACKNOWLEDGEMENT

Authors would like to thank the Mycology Unit staff at UKM Medical Centre for laboratory assistance. This study was funded by UKM Faculty of Medicine Fundamental Grant FF-226-2008.

References

1. Goreja WG: Tongkat Ali: tree that cures a hundred diseases. Amazing Herbs Press, 2004; New York
2. Goh SH, Hock CC, Mok JSL, Soepadmo E: Malaysian medicinal plants for the treatment of cardiovascular disease. Pelanduk Publication Sdn Bhd, 1995; Kuala Lumpur
3. Nguyen-Pouplin J, Tran H, Phan TA, Dolecek C, Farrar J, Tran TH, Caron P, Bodoa B, Grellier P: Antimalarial and cytotoxic activities of ethnopharmacologically selected medicinal plants from South Vietnam. *Jour Ethnopharm*; 2007;109:417–427.
4. Kirby GC, O'Neill MJ, Phillipson JD, Warhurst DC: In vitro studies on the mode of action of quassinoids with activity against chloroquine-resistant *Plasmodium falciparum*. *Biochem Pharm*; 1989;38(24):4367–4374.
5. Chan KL, Low BS, Teh CH, Das PK: The effect of *Eurycoma longifolia* on sperm quality of male rats. *Nat Prod Comm*; 2009;4(10):1331–1336.
6. Zanolli P, Zavatti M, Montanari C, Baraldi M: Influence of *Eurycoma longifolia* on the copulatory activity of sexually sluggish and impotent male rats. *Jour Ethnopharm*; 2009;126(2):308–313.
7. Wernsdorfer WH, Ismail S, Chan KL, Congpuong K, Wernsdorfer G: Activity of *Eurycoma longifolia* root extract against *Plasmodium falciparum* in vitro. *Wien Klin Wochenschr*; 2009;121(S3):23–26.
8. Zakaria Y, Rahmat A, Pihie AH, Abdullah NR, Houghton PJ: *Eurycomanone* induce apoptosis in HepG2 cells via up-regulation of p53. *Can Cell Int*; 2009;9:16–37.
9. Miyake K, Tezuka Y, Awale S, Li F, Kadota S : Quassinoids from *Eurycoma longifolia*. *Jour Nat Prod*; 2009;72(12):2135–2140.
10. Farouk AE, Benafri A: Antibacterial activity of *Eurycoma longifolia* Jack. A Malaysian medicinal plant. *Saudi Med Jour*; 2007;28(9):1422–1444.
11. Kuo PC, Damu AG, Lee KH, Wu TS: Cytotoxic and antimalarial constituents from the roots of *Eurycoma longifolia*. *Bio & Med Chem*; 2004;12(3):537–44
12. CLSI: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, 3rd Edition. CLSI document M27-A3. Wayne, PA; 2008; Clinical and Laboratory Standards Institute.
13. CLSI: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 8th Edition. CLSI document M07-A8. Wayne, PA; 2009; Clinical and Laboratory Standards Institute.
14. Katz ML, Mueller LV, Polyakov M, Weinstock SF: Where Have All The Antibiotic Patents Gone? *Nat Biotech*; 2006; 24(12):1529–1531.
15. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards Jr JE: Trends in antimicrobial drug development: implications for the future. *Clin Inf Dis*; 2004;38:1279–1286.
16. Coates A, Hu Y, Bax R, Page C: The future challenges facing the development of new antimicrobial drugs. *Nat Rev Drug Disc*; 2002;1:895–910.
17. Reynolds R, Potz N, Colman M, Williams A, Livermore

- D, MacGowan A: BSAC Extended Working Party on Bacteraemia Resistance Surveillance. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002; 2004; the BSAC Bacteraemia Resistance Surveillance.
18. Paterson DL: The epidemiological profile of infections with multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter* species. *Clin Inf Dis*; 2006; 43(S2):S43–S48.
19. Coates ARM, Hu Y: Novel approaches to developing new antibiotics for bacterial infections. *Brit J Pharm*; 2007;152:1147–1154.
20. Ng KP, Saw TL, Na SL, Soo-Hoo TS: Systemic *Candida* infection in University Hospital 1997-1999: the distribution of *Candida* biotypes and antifungal susceptibility patterns. *Mycopath*; 2001;149:141-146.
21. Tzar MN, Shamim AS Z: *Candidaemia* and antifungal susceptibility testing in a teaching hospital. *Med Jour Mal*; 2009;64(1):61-64.

Author Information

MN Tzar

Department of Medical Microbiology and Immunology, Universiti Kebangsaan Malaysia Medical Centre

Y Hamidah

Department of Medical Microbiology and Immunology, Universiti Kebangsaan Malaysia Medical Centre

S Hartini

Department of Medical Microbiology and Immunology, Universiti Kebangsaan Malaysia Medical Centre

M Marianayati

Department of Medical Microbiology and Immunology, Universiti Kebangsaan Malaysia Medical Centre

AS Nazrun

Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia